The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Improvement of cancer-targeting therapy, using nanocarriers for intractable solid tumors by inhibition of TGF-β signaling
Open accessAbstract
Transforming growth factor (TGF)-β plays a pivotal role in regulation of progression of cancer through effects on tumor microenvironment as well as on cancer cells. TGF-β inhibitors have recently been shown to prevent the growth and metastasis of certain cancers. However, there may be adverse effects caused by TGF-β signaling inhibition, including the induction of cancers by the repression of TGF-β-mediated growth inhibition. Here, we present an application of a short-acting, small-molecule TGF-β type I receptor (TβR-I) inhibitor at a low dose in treating several experimental intractable solid tumors, including pancreatic adenocarcinoma and diffuse-type gastric cancer, characterized by hypovascularity and thick fibrosis in tumor microenvironments. Low-dose TβR-I inhibitor altered neither TGF-β signaling in cancer cells nor the amount of fibrotic components. However, it decreased pericyte coverage of the endothelium without reducing endothelial area specifically in tumor neovasculature and promoted accumulation of macromolecules, including anticancer nanocarriers, in the tumors. Compared with the absence of TβR-I inhibitor, anticancer nanocarriers exhibited potent growth-inhibitory effects on these cancers in the presence of TβR-I inhibitor. The use of TβR-I inhibitor combined with nanocarriers may thus be of significant clinical and practical importance in treating intractable solid cancers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Matsumura, Y., & Maeda, H. (1986) · PubMed · Cited by 6,781
Burris, H. A., Moore, M. J., Andersen, J., Green, M. R., Rothenberg, M. L., Modiano, M. R., Cripps, M. C., Portenoy, R. K., Storniolo, A. M., Tarassoff, P., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.6.2403 · Cited by 5,894
Cancer nanotechnology: opportunities and challenges
Ferrari, M. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1566 · Cited by 4,558
Block copolymer micelles for drug delivery: design, characterization and biological significance
Kataoka, K., Harada, A., & Nagasaki, Y. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00124-1 · Cited by 3,506
Self-citationPolymer conjugates as anticancer nanomedicines
Duncan, R. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1958 · Cited by 1,962
SPECIFICITY AND VERSATILITY IN TGF-β SIGNALING THROUGH SMADS
Feng, X.-H., & Derynck, R. (2005) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.21.022404.142018 · Cited by 1,869
Imaging of angiogenesis: from microscope to clinic
McDonald, D. M., & Choyke, P. L. (2003) · Nature Medicine · doi:10.1038/nm0603-713 · Cited by 1,016
Tumor Vascular Permeability, Accumulation, and Penetration of Macromolecular Drug Carriers
Dreher, M. R., Liu, W., Michelich, C. R., Dewhirst, M. W., Yuan, F., & Chilkoti, A. (2006) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djj070 · Cited by 920
Defective Angiogenesis in Mice Lacking Endoglin
Li, D. Y., Sorensen, L. K., Brooke, B. S., Urness, L. D., Davis, E. C., Taylor, D. G., Boak, B. B., & Wendel, D. P. (1999) · Science · doi:10.1126/science.284.5419.1534 · Cited by 852
Oh, S. P., Seki, T., Goss, K. A., Imamura, T., Yi, Y., Donahoe, P. K., Li, L., Miyazono, K., ten Dijke, P., Kim, S., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.6.2626 · Cited by 851
Self-citationHirschi, K. K., Rohovsky, S. A., & D'Amore, P. A. (1998) · The Journal of Cell Biology · doi:10.1083/jcb.141.3.805 · Cited by 796
The two faces of transforming growth factor β in carcinogenesis
Roberts, A. B., & Wakefield, L. M. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1633291100 · Cited by 747
Bae, Y., Nishiyama, N., Fukushima, S., Koyama, H., Yasuhiro, M., & Kataoka, K. (2005) · Bioconjugate Chemistry · doi:10.1021/bc0498166 · Cited by 742
Self-citationNovel cisplatin-incorporated polymeric micelles can eradicate solid tumors in mice.
Nishiyama, N., Okazaki, S., Cabral, H., Miyamoto, M., Kato, Y., Sugiyama, Y., Nishio, K., Matsumura, Y., & Kataoka, K. (2003) · PubMed · Cited by 710
Self-citationHamaguchi, T., Matsumura, Y., Suzuki, M., Shimizu, K., Goda, R., Nakamura, I., Nakatomi, I., Yokoyama, M., Kataoka, K., & Kakizoe, T. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602479 · Cited by 565
Self-citationAbnormal angiogenesis but intact hematopoietic potential in TGF‐β type I receptor‐deficient mice
Larsson, J., Goumans, M., Sjöstrand, L. J., van Rooijen, M. A., Ward, D., Levéen, P., Xu, X., ten Dijke, P., Mummery, C. L., & Karlsson, S. (2001) · The EMBO Journal · doi:10.1093/emboj/20.7.1663 · Cited by 563
Fuchs, C. S., & Mayer, R. J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199507063330107 · Cited by 559
Development of TGF-β signalling inhibitors for cancer therapy
Yingling, J. M., Blanchard, K. L., & Sawyer, J. S. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1580 · Cited by 549
TGF-? receptor function in the endothelium
LEBRIN, F., DECKERS, M., BERTOLINO, P., & TENDIJKE, P. (2005) · Cardiovascular Research · doi:10.1016/j.cardiores.2004.10.036 · Cited by 513
Arteriovenous malformations in mice lacking activin receptor-like kinase-1
Urness, L. D., Sorensen, L. K., & Li, D. Y. (2000) · Nature Genetics · doi:10.1038/81634 · Cited by 440
Arthur, H. M., Ure, J., Smith, A. J. H., Renforth, G., Wilson, D. I., Torsney, E., Charlton, R., Parums, D. V., Jowett, T., Marchuk, D. A., et al. (2000) · Developmental Biology · doi:10.1006/dbio.1999.9534 · Cited by 436
Kano, M. R., Morishita, Y., Iwata, C., Iwasaka, S., Watabe, T., Ouchi, Y., Miyazono, K., & Miyazawa, K. (2005) · Journal of Cell Science · doi:10.1242/jcs.02483 · Cited by 277
Self-citationTakahashi, Y., Cleary, K. R., Mai, M., Kitadai, Y., Bucana, C. D., & Ellis, L. M. (1996) · PubMed · Cited by 244
Sawyer, J. S., Anderson, B. D., Beight, D. W., Campbell, R. M., Jones, M. L., Herron, D. K., Lampe, J. W., McCowan, J. R., McMillen, W. T., Mort, N., et al. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm0205705 · Cited by 236
Bandyopadhyay, A., Agyin, J. K., Wang, L., Tang, Y., Lei, X., Story, B. M., Cornell, J. E., Pollock, B. H., Mundy, G. R., & Sun, L.-Z. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3565 · Cited by 185
Watabe, T., Nishihara, A., Mishima, K., Yamashita, J., Shimizu, K., Miyazawa, K., Nishikawa, S.-I., & Miyazono, K. (2003) · The Journal of Cell Biology · doi:10.1083/jcb.200305147 · Cited by 176
Self-citationDifferential diagnosis of pancreatic tumors using ultrasound contrast imaging
Sofuni, A., Iijima, H., Moriyasu, F., Nakayama, D., Shimizu, M., Nakamura, K., Itokawa, F., & Itoi, T. (2005) · Journal of Gastroenterology · doi:10.1007/s00535-005-1578-z · Cited by 166
Hereditary Hemorrhagic Telangiectasia, a Vascular Dysplasia Affecting the TGF- Signaling Pathway
Fernandez-L, A., Sanz-Rodriguez, F., Blanco, F. J., Bernabeu, C., & Botella, L. M. (2006) · Clinical Medicine & Research · doi:10.3121/cmr.4.1.66 · Cited by 161
Peritoneal metastatic model for human scirrhous gastric carcinoma in nude mice
Yashiro, M., Chung, Y. S., Nishimura, S., Inoue, T., & Sowa, M. (1996) · Clinical & Experimental Metastasis · doi:10.1007/bf00157685 · Cited by 106
Self-citationMolecular therapy in pancreatic adenocarcinoma
MacKenzie, M. J. (2004) · The Lancet Oncology · doi:10.1016/s1470-2045(04)01565-7 · Cited by 73
Liposomal encapsulated anthracyclines: new therapeutic horizons
Muggia, F. M. (2001) · Current Oncology Reports · doi:10.1007/s11912-001-0016-5 · Cited by 68
(1989) · PubMed
Cited by
Accessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment
Hanahan, D., & Coussens, L. M. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.02.022 · Cited by 4,632
Bertrand, N., Wu, J., Xu, X., Kamaly, N., & Farokhzad, O. C. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.11.009 · Cited by 2,824
Nanoparticle-based targeted drug delivery
Singh, R., & Lillard, J. W. (2009) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2008.12.004 · Cited by 2,734
Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size
Cabral, H., Matsumoto, Y., Mizuno, K., Chen, Q., Murakami, M., Kimura, M., Terada, Y., Kano, M. R., Miyazono, K., Uesaka, M., et al. (2011) · Nature Nanotechnology · doi:10.1038/nnano.2011.166 · Cited by 2,429
Self-citationMaeda, H., Nakamura, H., & Fang, J. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.10.002 · Cited by 2,376
Metadata
- Authors
- Kano, M. R., Bae, Y., Iwata, C., Morishita, Y., Yashiro, M., Oka, M., Fujii, T., Komuro, A., Kiyono, K., Kaminishi, M., Hirakawa, K., Ouchi, Y., Nishiyama, N., Kataoka, K., & Miyazono, K.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2007-02-27
- Volume
- 104
- Issue
- 9
- Pages
- 3460-3465
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W1968762000
- Cited by
- 410
- References
- 32
- FWCI
- 6.70
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.